Ratlarda finasterid ve dutasteridin prostat vaskülaritesine etkisinin araştırılması

Abstract

Amaç: Finasterid ve dutasterid verilen ratların prostatlarında özellikle vasküler olmak üzere histopatolojik değişikliklerin araştırılması. Gereç ve Yöntemler: Çalışma grubundaki 20 adet Wistar Albino suşu rata günlük 80 mg/kg/gün finasterid n=10 veya 16 mg/kg/gün dutasterid n=10 , 15 gün boyunca orogastrik gavaj enjektörü ile verildi. Kontrol grubundaki 6 rata ilaç verilmedi. Deney sonunda ratlar anestezi ile sakrifiye edildikten sonra, testisleri, veziküla seminalisleri ve prostatları cerrahi olarak eksize edildi. Prostat kesitleri, endoteli işaretlemek için CD31 antikoru ile immünohistokimyasal olarak boyandı ve ışık mikroskobu altında incelendi. Ortalama mikrodamar yoğunluğu MDY , ortalama proliferatif mikrodamar yoğunluğu PMDY , ortalama damar alanı DAL ve ortalama damar çevresi uzunluğu DÇEV , 3 farklı alanda X200 büyütmede, dijital görüntüleme sistemi kullanılarak hesaplandı.Bulgular: Çalışma sonunda kontrol, finasterid ve dutasterid gruplarında prostat ağırlığı sırasıyla; 0.47±0.02 gr, 0.28±0.02 gr ve 0.19±0.02 gr olarak tespit edildi p=0.006 . Kontrol, finasterid ve dutasterid gruplarında MDY değerleri sırasıyla; 5.16, 11.66 ve 10.28 olarak bulundu p=0.001 . Kontrol, finasterid ve dutasterid gruplarında PMDY sırasıyla; 6.33, 15.23 ve 15.43 olarak saptandı p=0.001 . Dunificantly lower in dutasterid group compared to finasteride group 341.71 vs. 814.71 µm2, p=0.019 and 69.51 vs. 109.34 µm, p=0.007, respectively .Conclusion: In the dutasteride group there was a statistically significant decrease in the weight of the prostate gland at the end of study compared to the other groups. The MVD was significantly higher in dutasteride and finasteride group compared to control group, but not different between finasteride and dutasteride group.tasterid grubunda DAL ve DÇEV değerleri, finasterid grubuna göre anlamlı ölçüde düşük olarak bulundu 341.71’e karşı 814.71 µm2, p=0.019 ve 69.51’e karşı 109.34 µm, p=0.007 .Sonuçlar: Dutasterid grubunda, deney sonrası prostat ağırlığında diğer gruplara göre istatistiksel olarak anlamlı azalma mevcuttu. Dutasterid ve finasterid gruplarında MDY kontrol grubuna göre anlamlı ölçüde yüksek olduğu, fakat finasterid ve dutasterid verilen ratlarda farksız olduğu saptandı

Keywords

• Finasterid,Dutasterid

To investigate the effect of finasteride and dutasteride on rats prostate vascularity

Abstract

Objective: To investigate the histopathological changes, particularly vascular changes on prostate glands of the rats that were treated with finasteride and dutasteride. Material and Methods: Either finasteride 80 mg/kg/day n=10 or dutasteride 16 mg/kg/ day n=10 for 15 days were administered to 20 Wistar Albino rats dailly in study group with orogastric gavage syringe. No drugs were administered to the control group n=6 . At the end of the study, all rats were anesthetically sacrified and their testicles, seminal vesicles and prostates were excised surgically. Prostatic sections were stained with CD31 antibodies immunohistochemically to mark endothelium and were examined under light microscopy. The mean microvessel dansity MVD , mean proliferative MVD PMVD , mean vessel area MVA and the mean length of vessel circumference MVCD were measured in three different areas on X200 magnification by using digital imaging system. Results: The weight of the prostate at the end of the study in control, finasterid and dutasterid group was; 0.47±0.02 gr, 0.28±0.02 gr and 0.19±0.02 gr, respectively p=0.006 . The MVD in control, finasterid and dutasterid group were 5.16, 11.66 and 10.28, respectively p=0.001 . The PMVD in control, finasterid and dutasterid group was 6.33, 15.23 and 15.43, respectively p=0.001 . The MVA and the MVCD were significantly lower in dutasterid group compared to finasteride group 341.71 vs. 814.71 µm2 , p=0.019 and 69.51 vs. 109.34 µm, p=0.007, respectively . Conclusion: In the dutasteride group there was a statistically significant decrease in the weight of the prostate gland at the end of study compared to the other groups. The MVD was significantly higher in dutasteride and finasteride group compared to control group, but not different between finasteride and dutasteride group

Keywords

• Finasteride, Dutasteride

References

1. Berry SJ, Coffey DS, Walsh PC, Ewinq LL. The Development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-79.
2. Chute CG, Panser LA, Girman CJ et al. The prevelan- ce of prostatism: A Population-Based survey of urinary symptoms. J Urol 1993;150: 85-89.
3. Gu FL, Xia TL, Kong XT. Preliminary study of the frequ- ency of benign prostatic hyperplasia and prostatic cancer in China. Urology 1994;44: 688-99.
4. Kaya C, Ozyurek M, Turkeri LN. Comparison of microves- sel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study. Int J Urol 2005;12: 194-98.
5. Clark CV, Hermann DJ, Cunningham Gr et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reducta- se inhibitor. J Urol 2005;12: 514-15.
6. Foley CL, Kirby RS. 5 alpha-reductase inhibitors: what’s new?. Curr Opin Urol 2003;13: 31-37.
7. Pareek G, Shevchuk M, Armenakas NA et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169: 20-23.
8. Crea G, Sanfilippo G, Anastasi G et al. Pre-surgical finaste- ride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol İnt 2005;7: 51-53.

9. Hahn RG, Fagerstrom T, Tammela TL et al. Blood loss and postoperative complications associated with trasurethral re- section of the prostate after pretreatment with dutasteride. BJU Int 2007;99: 587-94.
10. Kyprianou N, Isaacs JT. Activation of programmed cell de- ath in the rat ventral prostate after castration. Endocrino- logy 1998;122: 552-53.
11. Rittmaster RS, Manning AP, Wright AS et al. Evidence for atrophy and apoptosis in the ventral rat prostate rats given the 5-alpha reductase inhibitor finasteride. Endocrinology 1995;136: 741-48.
12. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5: 545-57.
13. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997;25: 309-14.
14. Lekas E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 2000;85: 962-65.
15. Marks LS, Partin AW, Dorey FJ et al. Long-term effects of fi- nasteride on prostate tissue composition. Urology 1999;53: 574-80.
16. Marks LS, Partin AW, Gormley GJ et al. Prostate tissue com- position and response to finasteride in men with sympto- matic benign prostatic hyperplasia. J Urol 1997; 157: 2171- 78
17. Bailey DM, Foley SJ, Wedderburn A. Effect of finasteride on microvessl density(MVD) in patients with recurrent haematuria related to prostatic hypertrophy(BPH). J Urol 1999;161: 363-67.
18. Prahalada SR, Keenan KP, Hertzog PR et al. Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5 alpha-re- ductase inhibitor. Urology 1994;43: 680-85.
19. Weisser H, Krieg M. In vitro inhibition of androstenedione 5α-reduction by finasteride in epithelium and stroma of hu- man benign prostatic hyperplasia. J Steroid Biochem Molec Biol 1998;67: 49-55.
20. Tunn S, Hochstrate H, Grunwald I, Flüchter St H, Krieg M. Effect of aging on kinetic parameters of 5α-reductase in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1988;67: 979-85.
21. Rennie PS, Bruchovsky N, McLoughlin MG, Batzold FH, Dunstan-Adams EE. Kinetic analysis of 5α-reductase iso- enzymes in benign prostatic hyperplasia (BPH). J Steroid Biochem 1983;19: 169-73.